Home › Small Cell Lung Cancer › Washington
Small Cell Lung Cancer clinical trials in Washington
13 studies for Small Cell Lung Cancer are looking for participants at sites in Washington.
Cities in Washington
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Northwest Medical Specialties, Tacoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Sep 22, 2026 · NCT07006727Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- University of Washington Fred Hutchinson, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07564401A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Medical Center, Seattle
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06646276AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Seattle
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- Fred Hutch Cancer Research, Seattle
RecruitingPhase 1/2
Ages 18 to 100 · All sexes · Updated Aug 27, 2026 · NCT06726148A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- Northwest Cancer Specialists, Vancouver
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06095505A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- Fred Hutch Cancer Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05652686A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Swedish Cancer Institute, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07174583Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Swedish Cancer Institute, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 26, 2026 · NCT06598306A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 105, Spokane
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 21, 2025 · NCT05914116From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.